- Conditions
- Peripheral Vascular Disease
- Interventions
- Misago™ Self-Expanding Stent System
- Device
- Lead sponsor
- Terumo Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
- Interventions
- GORE® VIAFORT Vascular Stent
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 8
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
- Conditions
- Retinal Vein Occlusion
- Interventions
- Minocycline, Placebo, Bevacizumab
- Drug · Other
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thrombosis
- Interventions
- alteplase
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 28 Weeks to 66 Weeks
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Pain
- Interventions
- Clonidine, ropivacaine
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ureteropelvic Junction Obstruction, Ureteropelvic Junction; Obstruction, Congenital
- Interventions
- Parent Decision Aid
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Atherosclerosis, Peripheral Artery Disease, Intermittent Claudication, Chronic Total Aterial Occlusion
- Interventions
- MS-325 Injection (Gadofosveset Trisodium)
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ischemic Heart Disease
- Interventions
- Not listed
- Lead sponsor
- Piedmont Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Suspected CSF Shunt Obstruction
- Interventions
- ShuntCheck-Micro-Pumper (SCMP), Imaging
- Device
- Lead sponsor
- NeuroDx Development
- Industry
- Eligibility
- 35 Months to 29 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 11
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Bite Block
- Interventions
- bite block
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Coronary Occlusions
- Interventions
- Cypher sirolimus eluting coronary stent
- Device
- Lead sponsor
- Sunil Rao
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 13
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
- Conditions
- Thrombosis, Venous Thrombosis
- Interventions
- Alfimeprase
- Drug
- Lead sponsor
- ARCA Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Chronic Total Occlusion of Coronary Artery, Chronic Angina
- Interventions
- VasoStar guidewire system
- Device
- Lead sponsor
- VasoStar, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Akron, Ohio
- Conditions
- Catheter Occlusion, Thrombosis
- Interventions
- CUSA-081, Placebo, Alteplase
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Drug
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Marginal Ulcer, Chronic Ulcer Disease, Persistent Ulcer Disease, Recurrent Ulcer Disease, Late Morbidity After Gastric Bypass
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Fresno, California
- Conditions
- Retinal Vein Occlusions
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Retinal Vein Occlusion
- Interventions
- Nicotinic acid, Prednisolone acetate
- Drug
- Lead sponsor
- Palo Alto Medical Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Gastric Disease
- Interventions
- Novel Bite Block
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Peripheral Arterial Disease
- Interventions
- Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer
- Device
- Lead sponsor
- Avinger, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 10 more
- Conditions
- Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
- Interventions
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Houston, Texas • Katy, Texas • The Woodlands, Texas
- Conditions
- Macular Edema With Central Retinal Vein Occlusions
- Interventions
- Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Morbid Obesity, Bariatric Surgery Candidate
- Interventions
- Liposomal bupivacaine, Bupivacaine Injection
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Acute Ischemic Stroke
- Interventions
- RapidPulseTM Aspiration System
- Device
- Lead sponsor
- RapidPulse, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- Torrance, California • New Haven, Connecticut • Jacksonville, Florida + 15 more